Inmune Bio Confirms NASDAQ Listing in Routine 8-K Filing
Ticker: INMB · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, regulatory-filing, corporate-governance
TL;DR
**Inmune Bio filed a routine 8-K, confirming its NASDAQ listing.**
AI Summary
Inmune Bio, Inc. filed an 8-K on January 2, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates that the company's Common Stock, with a par value of $0.001 per share, is registered on The NASDAQ Stock Market LLC under the trading symbol INMB. For investors, this filing primarily serves as a routine update confirming the company's continued compliance with SEC reporting requirements and its listing on a major exchange, which is a positive sign of stability and accessibility for trading.
Why It Matters
This filing confirms Inmune Bio's continued listing on The NASDAQ Stock Market LLC, which is important for liquidity and investor confidence. It's a standard compliance update, not signaling any major operational changes.
Risk Assessment
Risk Level: low — This 8-K filing is a standard compliance report and does not disclose any new material risks or changes to the company's operations or financial health.
Analyst Insight
A smart investor would recognize this as a routine compliance filing that doesn't provide new material information for investment decisions. It confirms the company's ongoing listing on NASDAQ, which is a baseline expectation for a publicly traded company.
Key Numbers
- $0.001 — Par value per share (The stated par value of Inmune Bio's Common Stock.)
Key Players & Entities
- Inmune Bio, Inc. (company) — the registrant filing the 8-K
- The NASDAQ Stock Market LLC (company) — the exchange where Inmune Bio's common stock is registered
- $0.001 (dollar_amount) — par value per share of common stock
- INMB (company) — trading symbol for Inmune Bio's common stock
- January 2, 2024 (date) — date of the earliest event reported and filing date
FAQ
What is the purpose of Inmune Bio, Inc.'s 8-K filing dated January 2, 2024?
The 8-K filing by Inmune Bio, Inc. on January 2, 2024, is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
On which stock exchange is Inmune Bio, Inc.'s Common Stock registered?
Inmune Bio, Inc.'s Common Stock is registered on The NASDAQ Stock Market LLC, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the trading symbol for Inmune Bio, Inc.'s Common Stock?
The trading symbol for Inmune Bio, Inc.'s Common Stock is INMB, as indicated in the 'Title of each class' table within the filing.
What is the par value of Inmune Bio, Inc.'s Common Stock?
The par value of Inmune Bio, Inc.'s Common Stock is $0.001 per share, as specified in the 'Title of each class' section of the filing.
What is Inmune Bio, Inc.'s business address?
Inmune Bio, Inc.'s business address is 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, as listed in the 'BUSINESS ADDRESS' section of the filing.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-01-02 16:00:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea190996-8k_inmune.htm (8-K) — 23KB
- ea190996ex99-1_inmune.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-000240.txt ( ) — 220KB
- inmb-20240102.xsd (EX-101.SCH) — 3KB
- inmb-20240102_lab.xml (EX-101.LAB) — 33KB
- inmb-20240102_pre.xml (EX-101.PRE) — 22KB
- ea190996-8k_inmune_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On January 2, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that the Company's INKmune Phase I/II trial dosed the first patient in men with metastatic castration-resistant prostate cancer on December 27, 2023. A copy of the press release is attached herewith as Exhibit 99.1.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated January 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: January 2, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2